Hepion Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
HEPA$0.11-13.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)
| Preferred Stock · Preferred Stock · Additional · Accumulated other · Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Series A · Series C · Common Stock · Paid in · Comprehensive · Accumulated · Stockholders’ | ||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2023 | 85,581 | $855,808 | 1,688 | $839,320 | 4,818,733 | $482 | $230,291,362 | $(78,779) | $(224,627,386) | $7,280,807 |
| Net loss | — | — | — | — | — | — | — | — | (2,853,806) | (2,853,806) |
| Other comprehensive income (loss) | — | — | — | — | — | — | — | 87,979 | — | 87,979 |
| Stock-based compensation expense | — | — | — | — | — | — | 705,770 | — | — | 705,770 |
| Warrant exercises, net | — | — | — | — | 654,393 | 65 | 2,300,624 | — | — | 2,300,689 |
| Balance at March 31, 2024 | 85,581 | 855,808 | 1,688 | 839,320 | 5,473,126 | 547 | 233,297,756 | 9,200 | (227,481,192) | 7,521,439 |
| Net loss | — | — | — | — | — | — | — | — | (3,925,212) | (3,925,212) |
| Other comprehensive income (loss) | — | — | — | — | — | — | — | (63,022) | — | (63,022) |
| Stock-based compensation expense | — | — | — | — | — | — | 28,625 | — | — | 28,625 |
| Issuance of shares in abeyance | — | — | — | — | 326,000 | — | — | — | — | — |
| Balance at June 30, 2024 | 85,581 | $855,808 | 1,688 | $839,320 | 5,799,126 | $547 | $233,326,381 | $(53,822) | $(231,406,404) | $3,561,830 |
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Preferred Stock · Preferred Stock · Additional · Accumulated other · Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Series A · Series C · Common Stock · Paid in · Comprehensive · Accumulated · Stockholders’ | ||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2022 | 85,581 | $855,808 | 1,801 | $840,320 | 3,811,481 | $381 | $223,950,940 | $(90,168) | $(175,701,344) | $49,855,937 |
| Net loss | — | — | — | — | — | — | — | — | (13,259,921) | (13,259,921) |
| Other comprehensive income (loss) | — | — | — | — | — | — | — | 19,353 | — | 19,353 |
| Stock-based compensation expense | — | — | — | — | — | — | 537,123 | — | — | 537,123 |
| Conversion of Series C to common | — | — | (1) | (1,000) | 1 | — | 1,000 | — | — | — |
| Balance at March 31, 2023 | 85,581 | 855,808 | 1,800 | 839,320 | 3,811,482 | 381 | 224,489,063 | (70,815) | (188,961,265) | 37,152,492 |
| Net loss | — | — | — | — | — | — | — | — | (14,079,547) | (14,079,547) |
| Other comprehensive income (loss) | — | — | — | — | — | — | — | (16,836) | — | (16,836) |
| Stock-based compensation expense | — | — | — | — | — | — | 333,954 | — | — | 333,954 |
| Stock-based liability awards converted to equity | — | — | — | — | — | — | 2,983,006 | — | — | 2,983,006 |
| Issuance of common stock in connection with stock split | — | — | — | — | 26,807 | 3 | (3) | — | — | — |
| Balance at June 30, 2023 | 85,581 | $855,808 | 1,800 | $839,320 | 3,838,289 | $384 | $227,806,020 | $(87,651) | $(203,040,812) | $26,373,069 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.